Roivant posts $5.1B net income on $7.1B Telavant sale to Roche; cash at $6.7B

Roivant Sciences Ltd.

2023-Q3 EPS reported $5.46 revenue$95,865,000

Net income $5.1B ($6.37 basic EPS) vs loss of $384.9M a year ago, driven by $5.3B gain on Telavant sale.
Net cash proceeds from Telavant sale ~$5.2B; consolidated cash, cash equivalents and restricted cash $6.7B at Dec 31, 2023.
VTAMA net product revenue $20.7M for Q3; over 300k prescriptions written by ~14k prescribers since launch.
Batoclimab Phase 2 Graves' disease trial shows >50% response rate in initial cohort; additional data ongoing.
Non-GAAP net loss $174.9M; R&D expenses $123.7M; SG&A $197.3M; RVT-2001 development discontinued.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Roivant Sciences Ltd. reported financial results for the third quarter ended December 31, 2023.

Period: the third quarter ended December 31, 2023
Result: reported results

Exact text from the filing

Roivant Sciences Ltd. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended December 31, 2023.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Roivant Sciences Ltd. filing history →

Source: SEC EDGAR

accession 0001140361-24-007259

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.